Biocon Limited
Long

Biocon: Range to Trend Expansion in Progress

424
Biocon’s weekly chart highlights a well-structured range-bound consolidation transitioning into a rising trend. Over the past several quarters, the stock has repeatedly faced supply near the upper resistance zone around 400–420, as marked by multiple rejections. This clearly establishes a strong overhead resistance where sellers have historically dominated.

On the downside, price action has respected a rising support trendline, forming higher lows over time. Each dip toward this support zone has attracted fresh buying interest, indicating accumulation at lower levels. This combination of flat-to-rising resistance and rising support reflects improving demand strength and a gradual tightening of price structure.

The recent pullback toward the support area near 360–370 is technically healthy rather than bearish. Such retracements often act as retest phases, allowing the market to absorb supply before attempting the next directional move. As long as Biocon holds above this rising support, the broader bullish structure remains intact.

A decisive weekly close above the resistance band (420+) would confirm a breakout from this prolonged consolidation. Post-breakout, the chart opens room for a strong upside expansion, with projected targets gradually extending toward the 460–500 zone based on the height of the prior range and trend continuation principles.

From a risk perspective, the setup stays valid while price sustains above the rising trendline. A breakdown below this support would delay the bullish thesis and could push the stock back into consolidation. Until then, Biocon remains in a favorable positional structure, where patience around support and confirmation near resistance can offer high-quality risk–reward opportunities for medium- to long-term traders and investors.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.